The FDA recently approved a pioneering CRISPR–Cas9 therapy for sickle cell disease, marking a historic moment in genetic treatment. But that it is just the tip of the iceberg.
The approvals include the first-ever CRISPR-Cas9 based drug, Casgevy, and a gene therapy drug, Lyfgenia, marking a milestone in medical biotechnology.
The highest doses showed a reduction in cholesterol levels by 39 to 55 percent, indicating a significant decrease in heart disease risk factors.
In groundbreaking use of CRISPR gene-editing technology, scientists have engineered flu-resistant chickens. This is a first step towards reducing avian flu outbreaks.
Bacteria use a "scissors" system called CRISPR-Cas against viruses, and scientists have now discovered that complex cells, like ours, have a similar tool too.